Should intermittent androgen deprivation be used in routine clinical practice?

Journal of Clinical Oncology

Volumn 23, Issue 32, 2005, Pages 8212-8218

  Bhandari, Manish S ^a   Crook, Juanita ^a   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; DUTASTERIDE; FINASTERIDE; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CLONAL VARIATION; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DISEASE COURSE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; MALE; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS, PHASE III; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS;

EID: 33644664272     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.2557     Document Type: Review

References (44)

1. Hunter J: Observations on certain parts of the animal economy (ed. 1). London, United Kingdom, Bibliotheca Osteriana, 1786:38-39.
2. Berthold AA: Transplantation der Hoden. Arch Anat Physiol Wiss Med 1:42-46, 1849
3. Cabot AT: The question of castration for enlarged prostate. Ann Surg 24:265, 1986
4. White JW: The present position of the surgery of the hypertrophied prostate. Ann Aurg. 10:152-156, 1984
5. Bulun SE, Hadais EY: Chapter 4: Reproduction in Williams RH, Larsen PR, Kronenberg HM, et al: Williams Textbook of Endocrinology (ed 10). Philadelphia, PA, W.B. Saunders Company, 2003
6. Huggins C, Stevens RE Jr, Hodges CV: Studies on prostatic cancer, II: The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223, 1941
7. Huggins C, Hodges CV: Studies on prostate cancer, I: The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
8. Denis L, Murphy GP: Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 12:3888-3895, 1993 (suppl)
9. Whitmore WF: The natural history of prostatic cancer. Cancer 5:1104-1112, 1973
10. Denis LJ: Controversies in the management of localized and metastatic prostate cancer. Eur J Cancer 27:333-341, 1991
11. Bhandari M, Petrylak DP, Hussain M: Clinical trials in metastatic prostate cancer: Has there been real progress in the past decade? Eur J Cancer 41:941-953, 2005
12. Thompson CA, Shanafelt TD, Loprinzi CL: Andropause: Symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8:474-487, 2003
13. Wu CP, Gu FL: The prostate in eunuchs. Prog Clin Biol Res 370:249-255, 1991
14. Bruchovsky N, Lesser B, Van Doom E, et al: Hormonal effects on cell proliferation in rat prostate. Vitam Horm 33:61-102, 1975
15. Wu JP, Gu FL: The prostate 41-65 years post castration: An analysis of 26 eunuchs. Chin Med J (Engl) 100:271-272, 1987
16. McLeod DG: Hormonal therapy: Historical perspective to future directions. Urology 61:3-7, 2003
17. Bonkhoff H, Remberger K: Differentiation pathways and histogenic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 28:98-106, 1996
18. Berges RR, Furuya Y, Remington L, et al: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 90:8910-8914, 1993
19. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41:5070-5075, 1981
20. Noble RL. Hormonal control of growth and progression tumors of NB rates and theory of action. Cancer Res 37:82-94, 1977
21. Pfiel K, Eder IE, Putz T, et al: Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cell. Prostate 58:259-268, 2004
22. Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-35, 2001
23. Debes JO, Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Eng J Med. 351:1488-1490, 2004
24. Mellinghoff IK, Vivanco I, Kwon A, et al: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-527, 2004
25. Bruchovsky N, Rennie PS, Goldman AJ, et al: Effects of androgen withdrawal on the stern cell composition of the Shionogi carcinoma. Cancer Res 50:2275-2283, 1990
26. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate-specific antigen Cancer 52:1598-1605, 1993
27. Cleave ME, Hsieh JT, Wu HC, et al: Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52:1598-1605, 1992
28. Akakura K, Bruchovsky N, Goldenberg SL, et al: Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate specific antigen. Cancer 71:2782-2790, 1993
29. Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58:2546-2550, 1986 [Erratum: Cancer 59:43, 1987]
30. Goldenberg SL, Bruchovsky N, Gleave ME, et al: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45:839-844, 1995
31. Higano CS, Ellis W, Russell K, et al: Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 48:800-804, 1996
32. Tunn UW: Intermittent endocrine therapy of prostate cancer. Eur Urol 30:22-25, 1996 (suppl 1)
33. Oliver RT, Williams G, Paris AM, et al. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 49:79-82, 1997
34. Theyer G, Holub S, Durer A, et al: Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer 75:1515-1518, 1997
35. Norwich A, Huddart RA, Gadd J, et al: A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 81:96-99, 1998
36. Bruchovsky N, Klotz LH, Crook JM, et al: A phase II study of intermittent androgen suppression in men with a rising serum PSA after radiation for localized prostate cancer. Clin Invest Med 20:A378, 1997
37. Crook JM, Szumacher E, Malone S, et al: Intermittent androgen suppression in the management of prostate cancer. Urology 53:530-534, 1999
38. Strum SB, Scholz MC, McDermed JE: Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy. Oncologist 5:45-52, 2000
39. Grossfeld GD, Chaudhary UB, Reese DM, et al: Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58:240-245, 2001
40. De La Taille A, Zerbib M, Conquy S, et al: Intermittent androgen suppression in patients with prostate cancer. BJU Int 91:18-22, 2003
41. Sadar MD, Hussain M, Bruchovsky N: Prostate cancer: Molecular biology of early progression to androgen independence. Endocr Relat Cancer 6:487-502, 1999
42. Ross RW, Small EJ: Osteoperosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:1952-1956, 2002
43. Jiang PY, Higano S: The dynamics of bone mineral density during intermittent androgen suppression in prostate cancer patients without bone metastases. Proc Am Soc Clin Oncol 20:789a, 2002
44. Tunn UW, Kurek, R, Kienle E, et al. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy. J Urol 171:384, 2004 (abstr 1458)